Colleen Cuffaro

healthcare VC @canaanpartners

[Colleen Cuffaro @ColleenCuffaro]

@michael_gilman @ArrakisTx I actually don’t have access either but rest assured I brag about the amazing things happening at Arrakis in every convo I have!

[Halda Therapeutics @HaldaTx]

Halda unveils its first pipeline data for RIPTAC™ therapeutics, a new drug modality, at ASCO #GU23 Symposium. Preclinical data for a prostate cancer RIPTAC therapeutic demonstrates superior in vivo efficacy to standard of care.
#RIPTACtherapeutics
https://t.co/fYPtwV9xwh

[Colleen Cuffaro @ColleenCuffaro]

@SaraNayeem Agree and enjoyed the time we got to spend together!

[The New England Venture Capital Association @NewEnglandVC]

Bonkers with excitement as we launch ticket sales for the 10th Annual NEVY Awards, welcoming you to celebrate 10 Mad Years with us!

Buy your ticket for NEVYs in Wonderland on 12/8 – inventory is limited: https://t.co/2XHCASdlzq

#NEVYs22 #NEVYsInWonderland

[Colleen Cuffaro @ColleenCuffaro]

@nlonberg No one told you?!?

[Colleen Cuffaro @ColleenCuffaro]

@ranjitbindra So happy for you!

[Colleen Cuffaro @ColleenCuffaro]

@carolysuh @rtnarch Congrats Carol!

[Colleen Cuffaro @ColleenCuffaro]

@SamTruex Congrats, Sam!

[Endpoints News @endpts]

Cancer mutates a lot, Tyra Biosciences CEO Todd Harris said. And sometimes, that causes targeted therapies to stop working. On Wednesday, he unveiled a $106 million Series B round to address acquired resistance.

https://t.co/3mbCM7aXlq

[Endpoints News @endpts]

Day One’s mission is centered around improving the landscape for pediatric cancers, an area that the company says pharma has left behind over the last several years.

https://t.co/z5J4wF4iO4

[Colleen Cuffaro @ColleenCuffaro]

@ArrakisTx @alexseletsky How cool is that?! Awesome, Alex!

[Colleen Cuffaro @ColleenCuffaro]

THIS is why we do what we do.

[Canaan @canaanpartners]

Just announced: Promising results from @DayOneBio's Phase 1 study, and the stakes couldn't be higher. "Children with cancer and their families are waiting for more options," says CEO Jeremy Bender. Learn more: https://t.co/bfQvFkUziO

[Colleen Cuffaro @ColleenCuffaro]

@r_devraj @LillyPad @DisarmTx Congrats Raj and the whole Disarm team!

[John J. Pacifico @johnjpacifico]

Announcing our $800M Fund XII - very grateful to my colleagues, our investors and all the incredible entrepreneurs we serve who helped make this new fund possible.

[Canaan @canaanpartners]

👋👋👋

[Nina Kjellson @nkjellson]

We couldn’t be happier to have Jeremy formally back in the ⁦@canaanpartners family - friend, colleague and cancer-warrior! Childhood cancer-focused Day One snags Gilead alum Bender for CEO | FierceBiotech https://t.co/qBL0FyKjBZ

[Colleen Cuffaro @ColleenCuffaro]

@CraigMCrews @AlabiBorteley @HHMINEWS Congrats Shanique!

[Julie Papanek Grant @JuliePapanek]

Jackie Grant, an exceptional black woman PhD investor @Abingworthbio, discusses causes of the lack of racial diversity in #venturecapital and offers advice about how to make change. She nails the economic incentives, social pacts, and biases. @IAmBiotech #blm /n

[Colleen Cuffaro @ColleenCuffaro]

Congrats to the Tizona team and @nkjellson!

[FierceBiotech @FierceBiotech]

Gilead wants access to the biotech’s other main asset, TTX-080. For this, it has penned a $300 million pact to acquire a 49.9% equity interest in Tizona, with an option to buy out the biotech in full for a further $1.25 billion https://t.co/QKnok1spTB

[Colleen Cuffaro @ColleenCuffaro]

@5amVentures @MiraChaurushiya Congrats to all especially Jamil, Mira and Jason. A great team you have there, 5AM!